IThis listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



I

in which

Het denotes a mono- or bicyclic aromatic heterocyclic radical having from 1 to 3 N, O and/or S atoms which is mono- or disubstituted by Hal,

R^1 denotes A, which may be mono-, di- or trisubstituted by $S(O)_mA$, Ph, NH_2, NHA, NA_2, OH, OA, $PO(OA)_2$, ethynyl, vinyl or $O(CH_2)_nPh$,

R^2 denotes H, Hal or A,

R^3 denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,

A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms,

Ph denotes phenyl,

Hal denotes F, Cl, Br or I,

n denotes 1, 2, 3, 4, 5 or 6,

m denotes 0, 1 or 2,

and pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently Amended) Compounds according to Claim 1, in which

R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA,

~~and~~or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1, in which

R^3 denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

~~and~~or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to claim 1, in which

R^2 denotes H, methyl or F,

~~and~~or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

5. (Previously Presented)Compounds according to claim 1, in which

Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl

or oxazolyl, each of which is mono- or disubstituted by Hal,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently Amended) ~~Compo unds~~Compounds according to claim 1, in which

Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl or oxazolyl, each of which is mono- or disubstituted by Hal,

R^1 denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA,

R^2 denotes H, Hal or A,

R^3 denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms,

Ph denotes phenyl,

Hal denotes F, Cl, Br or I,

n denotes 1, 2, 3, 4, 5 or 6,

m denotes 0, 1 or 2,

~~and~~or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to Claim 1 of the formula~~selected from the group consisting of~~

1-(5-chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-propylsemicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-

(prop-2-ynyl)semicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,

1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,

1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-2-benzylsemicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,

1-(5-bromothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(3-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,

1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

1-(5-bromothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

~~and~~or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~and~~or pharmaceutically usable ~~derivatives, solvates,~~comprising salts ~~and~~or stereoisomers thereof, ~~characterised in that~~comprising reacting

a) a compound of the formula II



II

in which

R^1, R^2 and R^3 have the meaning indicated in Claim 1,

~~is reacted~~ with a compound of the formula III

Het-CO-L III

in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

Het has the meaning indicated in Claim 1,

and/or converting

a base or acid of the formula I ~~is converted~~ into one of its salts.

9. (Currently Amended) ~~Compounds~~A method of inhibiting coagulation factor Xa, comprising administering to a host in need thereof, a compound of the formula I according to claim 1 ~~as inhibitors of coagulation factor Xa~~.

10. (Currently Amended) ~~Compounds~~A method of inhibiting coagulation factor VIIa, comprising administering to a host in need thereof, a compound of the formula I according to claim 1 ~~as inhibitors of coagulation factor VIIa~~.

11. (Currently Amended) ~~Medicaments~~a pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios, and~~, if desired,~~pharmaceutically acceptable excipients and/or adjuvants.

12. (Currently Amended) ~~Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and~~A pharmaceutical composition according to claim 11, further comprising at least one further medicament active ingredient.

13. (Currently Amended) ~~Use of compounds according to claim 1 and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament~~A method for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically usable ~~derivatives, solvates,~~ salts ~~and~~or stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

15. (Currently Amended) ~~Use of compounds of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament~~A method for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios, in combination with at least one further medicament active ingredient.

16. (New) A method for the treatment of thromboembolic diseases, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

17. (New) A method for the treatment of thrombosis, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.